Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group Company Limited has entered into an exclusive licensing agreement with Guangzhou Lupeng Pharmaceutical Co., Ltd. to develop and commercialize the drug LP-168 in China. The agreement includes milestones and royalty payments that could total up to RMB729 million. LP-168, currently in Phase II clinical trials, is a promising treatment for non-tumor indications and is part of Hansoh’s strategic growth in the pharmaceutical industry.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.